PRLD Earnings

PRLD reported its FY2025Q4 earnings on 2026-02-16, showcasing a revenue of 0.00 against an estimate of 0.00, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.33 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following PRLD's FY2025Q4 earnings announcement on 2026-02-16, the stock price moved by % on the day of the release. Over the subsequent five days, it saw a % change. Historically, PRLD's stock price tends to shift by an average of +6.61% in the 10 days leading up to earnings and +19.08% in the 10 days following, providing insight into potential market.

For , analysts estimate PRLD’s annual revenue to reach , while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates Revise Upward by 75.71% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between PRLD's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved Revise Upward by 75.71% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, PRLD's stock price typically moves by +6.61% in the 10 days before its earnings and +19.08% in the 10 days after. For the upcoming earnings, analysts expect an EPS of 0.00 and revenue of .

The earnings call reveals a mixed outlook. Financially, the $60 million from Incyte is positive, but the lack of clear guidance and competitive pressures in the oncology market are concerning. The strategic partnership with Incyte and robust preclinical models are positive, but significant regulatory and execution risks remain. The Q&A highlighted competitive pressures and uncertainties in timelines, suggesting a cautious market response. Overall, the sentiment is balanced, leading to a neutral prediction for stock movement.